Purchase will accelerate development of multiplex immunoassays for cell signaling
BILLERICA, Mass.--(BUSINESS WIRE)--Millipore Corporation (NYSE: MIL), a leading provider of technologies, tools and services for the global life science industry, today announced that it has purchased the assets associated with Epitome Biosystems’ EpiTag™ technology. The purchase price was not disclosed.
The technology acquisition will enable Millipore’s Bioscience Division to expand its presence in the fast growing multiplex immunoassay market by offering scientists a broader portfolio of cell signaling assays that can be used with the Luminex xMAP® platform. Additionally, the acquisition will allow for the future development of other novel profiling technologies.
“Our multiplex offering is one of our fastest growing product lines and the acquisition of the EpiTag technology will help us to accelerate our product development and expand our growth prospects in this dynamic market,” said Rick Ryan, Vice President of Millipore’s Drug Discovery Business Unit. ”Our customers are interested in better understanding the roles that cell pathways play in major diseases such as cancer and diabetes. The EpiTag technology will allow us to develop multiplex immunoassays for cellular targets that were previously very difficult to detect and quantify. As a result, we will enable customers to leverage the power of the Luminex xMAP platform for cell signaling by providing antibodies and kits that are specific to the highest areas of interest for researchers.”
The ability of scientists to leverage multiplex cell signaling assays as a research tool has historically been limited due to the lack of highly-specific antibodies for intra-cellular targets. The EpiTag technology uses a bioinformatics-driven approach to develop high quality antibodies that are more specific and selective than other reagents on the market today. Using the EpiTag technology, Millipore expects to develop a new range of multiplex immunoassay kits that will enable researchers to more efficiently measure, detect and analyze proteins and cell signaling pathways.
Millipore is one of the industry’s pioneers in developing multiplex kits and reagents and is a leader in providing assays for markets such as immunology, inflammation, and metabolic diseases (diabetes, obesity, cardiovascular). The Company’s MILLIPLEX™ MAP assays provide scientists with the sensitivity, specificity, and reproducibility they require to tackle complex research problems. Additionally, Millipore offers unparalleled technical support—scientists working with scientists—to allow researchers to spend less time running their assays and spend more time advancing their research.
For additional information about Millipore’s broad range of multiplex immunoassay kits, please call 1-800-MILLIPORE or visit www.millipore.com/analytes
About Millipore
Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world’s challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 5,900 employees in 30 countries worldwide. For more information, visit www.millipore.com
Safe Harbor Statement
The matters discussed herein, as well as in future oral and written statements by management of Millipore Corporation that are forward-looking statements, are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements.
Potential risks and uncertainties that could affect Millipore's future operating results include, without limitation, the inability to successfully integrate the EpiTag technology assets or other acquired businesses or technologies; failure to achieve the synergies and sales expectations relating to these acquisitions; failure to achieve design wins into our pharmaceutical and biotechnology customers’ manufacturing design phase for a particular drug; delay, suspension or termination of a customer’s volume production; lack of availability of raw materials or component products on a timely basis; regulatory delay in the approval of new therapeutics; limitations on cash flow for operations and investment due to increased debt service obligations; the inability to establish and maintain necessary product and process quality levels; reduced demand for cell culture products using bovine serum; the inability to realize the expected benefits of development, marketing, licensing and other alliances; competitive factors such as new membrane or chromatography technology; the inability to achieve anticipated cost benefits of our supply chain initiative; risks relating to our concentration of principal manufacturing operations; the inability to utilize technology in current or planned products due to overriding rights by third parties; potential environmental liabilities; conditions in the economy in general and in the bioscience and bioprocess markets in particular; foreign exchange fluctuations; reduced private and government research funding; exposure to product liability claims; and difficulties inherent in transferring or outsourcing of manufacturing operations. Please refer to our filings with the SEC, including our most recent Annual Report on Form 10-K, for more information on these and other risks that could cause actual results to differ.
